0.00
price down icon100.00%   -63.48
 
loading
Schlusskurs vom Vortag:
$63.48
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$11.52B
Einnahmen:
$4.42B
Nettoeinkommen (Verlust:
$-413.00M
KGV:
0.00
EPS:
-2.27
Netto-Cashflow:
$99.00M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
Value
$0.00
$0.00
1-Wochen-Bereich:
Value
$0.00
$0.00
52-Wochen-Spanne:
Value
$0.00
$63.50

Catalent Inc Stock (CTLT) Company Profile

Name
Firmenname
Catalent Inc
Name
Telefon
(732) 537-6200
Name
Adresse
14 SCHOOLHOUSE ROAD, SOMERSET, NJ
Name
Mitarbeiter
0
Name
Twitter
@catalentpharma
Name
Nächster Verdiensttermin
2024-11-13
Name
Neueste SEC-Einreichungen
Name
CTLT's Discussions on Twitter

Vergleichen Sie CTLT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
CTLT
Catalent Inc
0.00 11.52B 4.42B -413.00M 99.00M -2.27
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
154.44 65.50B 9.26B 2.49B 2.30B 5.47
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.18 46.99B 30.25B 1.37B 5.08B 0.4257
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.23 45.96B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
15.06 17.04B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
296.69 12.77B 2.76B 1.11B 898.10M 22.77

Catalent Inc Stock (CTLT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-11-16 Hochstufung Robert W. Baird Neutral → Outperform
2023-09-05 Hochstufung Argus Hold → Buy
2023-07-20 Eingeleitet Wells Fargo Equal Weight
2023-07-05 Fortgesetzt JP Morgan Neutral
2023-06-14 Herabstufung Jefferies Buy → Hold
2023-05-22 Herabstufung JP Morgan Overweight → Neutral
2023-05-15 Herabstufung Deutsche Bank Buy → Hold
2023-05-08 Herabstufung BofA Securities Neutral → Underperform
2023-04-17 Herabstufung Robert W. Baird Outperform → Neutral
2023-04-14 Herabstufung William Blair Outperform → Mkt Perform
2023-04-10 Hochstufung Deutsche Bank Hold → Buy
2023-04-03 Herabstufung Barclays Overweight → Equal Weight
2022-12-19 Herabstufung KeyBanc Capital Markets Overweight → Sector Weight
2022-11-07 Herabstufung Argus Buy → Hold
2022-11-02 Herabstufung BofA Securities Buy → Neutral
2021-12-16 Eingeleitet Barclays Overweight
2020-12-10 Hochstufung KeyBanc Capital Markets Sector Weight → Overweight
2020-06-25 Eingeleitet Argus Buy
2020-04-21 Eingeleitet RBC Capital Mkts Outperform
2020-03-02 Eingeleitet Deutsche Bank Hold
2019-10-17 Fortgesetzt Stephens Overweight
2019-08-28 Herabstufung KeyBanc Capital Markets Overweight → Sector Weight
2019-06-21 Hochstufung Jefferies Hold → Buy
2019-04-16 Hochstufung UBS Neutral → Buy
2018-11-07 Hochstufung First Analysis Sec Neutral → Outperform
2018-10-09 Eingeleitet UBS Neutral
2018-03-28 Hochstufung KeyBanc Capital Mkts Sector Weight → Overweight
2018-03-21 Hochstufung Raymond James Mkt Perform → Outperform
2018-02-06 Herabstufung Stephens Overweight → Equal-Weight
2017-09-21 Hochstufung Morgan Stanley Equal-Weight → Overweight
2017-09-13 Eingeleitet Needham Hold
2017-09-08 Herabstufung KeyBanc Capital Mkts Overweight → Sector Weight
2016-12-01 Eingeleitet Goldman Neutral
2016-10-20 Eingeleitet KeyBanc Capital Mkts Overweight
2016-06-21 Hochstufung Wells Fargo Market Perform → Outperform
2016-06-20 Hochstufung BofA/Merrill Neutral → Buy
Alle ansehen

Catalent Inc Aktie (CTLT) Neueste Nachrichten

pulisher
Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025
pulisher
Apr 23, 2025

Silexion Partners With Catalent To Advance SIL204 SiRNA Therapy For KRAS-Driven Cancers - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics Enters Strategic Collaboration with Catalent to Advance SIL204 Development for KRAS-Driven Cancers - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Major Breakthrough: Silexion's Multi-KRAS Cancer Drug Enters Manufacturing Phase with Industry Giant Catalent - Stock Titan

Apr 23, 2025
pulisher
Apr 20, 2025

Lisata Therapeutics talks ADC breakthrough with Catalent – ICYMI - Proactive financial news

Apr 20, 2025
pulisher
Apr 17, 2025

Lisata Therapeutics announces research license with Catalent - MSN

Apr 17, 2025
pulisher
Apr 16, 2025

Lisata Therapeutics CMO discusses potential for certepetide under Catalent license agreement - Proactive financial news

Apr 16, 2025
pulisher
Apr 16, 2025

Lisata, Catalent partner for cancer drug research - Investing.com

Apr 16, 2025
pulisher
Apr 15, 2025

Lisata, Catalent partner for cancer drug research By Investing.com - Investing.com South Africa

Apr 15, 2025
pulisher
Apr 15, 2025

Lisata Therapeutics (LSTA) Partners with Catalent on Preclinical Study | LSTA Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Lisata Therapeutics Announces Research License with Catalent - GlobeNewswire

Apr 15, 2025
pulisher
Apr 15, 2025

Lisata Therapeutics, Inc. Announces Research License with Catalent, Inc - marketscreener.com

Apr 15, 2025
pulisher
Apr 13, 2025

Catalent Announces the Appointment of David Schaffer to Biologics Advisory Board - marketscreener.com

Apr 13, 2025
pulisher
Apr 07, 2025

Catalent's Journey Of Continuous Improvement For CSV Excellence - Bioprocess Online

Apr 07, 2025
pulisher
Apr 07, 2025

Trump’s Tariff Threat Sparks Race to Find US Drug Manufacturers - Yahoo Finance

Apr 07, 2025
pulisher
Mar 18, 2025

Jupiter Neurosciences, Catalent Partner to Produce JOTROL Softgels for Upcoming Trial - Contract Pharma

Mar 18, 2025
pulisher
Mar 13, 2025

CRDMO Market Research 2025: A Highly Competitive $328 Billion Market by 2029 with Lonza Group, WuXi, Catalent, Sai Life Sciences, Syngene, Jubilant Biosys, and Thermo Fisher Scientific Leading - Yahoo Finance

Mar 13, 2025
pulisher
Mar 07, 2025

Unit Dose Manufacturing Industry Report 2025-2030: Market to Cross $150.6 Billion Led by Catalent, Unither Pharmaceuticals, and Thermo Fisher Scientific - Yahoo Finance

Mar 07, 2025
pulisher
Mar 05, 2025

Global Cell and Gene Therapy Manufacturing Market to Reach ~USD 10 Billion by 2032 | DelveInsight - GlobeNewswire

Mar 05, 2025
pulisher
Mar 03, 2025

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Catalent, Inc. (CTLT) Investigation - ACCESS Newswire

Mar 03, 2025
pulisher
Feb 28, 2025

Healthcare CMO Market Projected To Witness Substantial Growth, 2025-2032: Lonza Group, Catalent, Inc., Aenova - EIN News

Feb 28, 2025
pulisher
Feb 27, 2025

Per-Encounter Medical Market to Witness Remarkable Growth with Catalent Inc., Smiths Medical Inc., Cardinal Health - openPR

Feb 27, 2025
pulisher
Feb 21, 2025

Catalent announces new board appointments - ROI-NJ

Feb 21, 2025
pulisher
Feb 20, 2025

Catalent Appoints Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors - citybiz

Feb 20, 2025
pulisher
Feb 20, 2025

Catalent Announces New Board Appointments - Business Wire

Feb 20, 2025
pulisher
Feb 10, 2025

Novo to grow Catalent? Rumor mill spins amid Trump tariff threat - BioProcess Insider

Feb 10, 2025
pulisher
Feb 07, 2025

Jupiter Neurosciences partners with Catalent for Parkinson's trial - MSN

Feb 07, 2025
pulisher
Feb 04, 2025

Ardena Acquires Catalent’s Drug Product Manufacturing Facility in Somerset, NJ - Contract Pharma

Feb 04, 2025
pulisher
Feb 04, 2025

Ardena Completes Acquisition of Advanced Drug Product Manufacturing Facility from Catalent and Expands Bioanalytical Services in North America - Yahoo Finance

Feb 04, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences Partners With Catalent For Parkinson's JOTROL Trial Production - Nasdaq

Feb 03, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences Signs Manufacturing Deal With Catalent Pharma for Jotrol Softgel Capsules - Marketscreener.com

Feb 03, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences Partners with Catalent to Produce JOTROL Softgels for Upcoming Clinical Trial - Contract Pharma

Feb 03, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences partners with Catalent for Parkinson's trial By Investing.com - Investing.com South Africa

Feb 03, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson's Trial - The Manila Times

Feb 03, 2025
pulisher
Feb 03, 2025

Jupiter Neurosciences Announces JOTROL Manufacturing - GlobeNewswire

Feb 03, 2025
pulisher
Feb 03, 2025

Major Breakthrough: New Parkinson's Drug Manufacturing Deal Could Fast-Track Treatment for 10M Patients - StockTitan

Feb 03, 2025
pulisher
Feb 03, 2025

How Novo’s Acquisition Of Catalent Cleared European Regulators - Citeline

Feb 03, 2025
pulisher
Jan 28, 2025

Catalent (CTLT) to Report Q2 Earnings: What's in the Cards? - MSN

Jan 28, 2025
pulisher
Jan 28, 2025

Catalent (NYSE:CTLT) Now Covered by StockNews.com - Defense World

Jan 28, 2025
pulisher
Jan 26, 2025

Pace Life Sciences Expands Capacity and Capability With Acquisition of Catalent’s Analytical Services Laboratory in Research Triangle Park - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 23, 2025

Catalent's Award-Winning Innovations and Community Engagement Initiatives - Pharmaceutical Technology

Jan 23, 2025
pulisher
Jan 23, 2025

Catalent to make CAR-T for Galapagos; Kindeva gets $129M for nerve agent antidote - Endpoints News

Jan 23, 2025
pulisher
Jan 22, 2025

Catalent backs decentralised manufacture of Galapagos’ CAR-T therapy - MSN

Jan 22, 2025
pulisher
Jan 22, 2025

Catalent to further expand Galapagos’ decentralized CAR-T manufacturing network in US - Indian Pharma Post

Jan 22, 2025
pulisher
Jan 21, 2025

Catalent to support Galapagos’ decentralized cell therapy approach - The Pharma Letter

Jan 21, 2025
pulisher
Jan 21, 2025

Catalent to Support Galapagos’ Decentralized CAR-T Therapy Trials - Contract Pharma

Jan 21, 2025

Finanzdaten der Catalent Inc-Aktie (CTLT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$294.26
price up icon 0.06%
$107.72
price up icon 1.31%
$8.29
price up icon 2.09%
$102.37
price up icon 1.07%
$15.31
price up icon 2.12%
$28.04
price up icon 0.68%
Kapitalisierung:     |  Volumen (24h):